{
}
UBS warns that higher capital requirements could increase operational costs, potentially squeezing margins even as the bank anticipates revenue growth. This situation poses challenges for balancing profitability without burdening consumers, impacting various sectors and overall economic health. As regulatory pressures mount globally, UBS's stance reflects a shift towards long-term stability, emphasizing the need for strategic agility in navigating stricter financial frameworks.
UBS benefits from a de facto state guarantee, leading to an estimated annual subsidy of CHF 2.6 billion due to reduced financing costs, according to a University of Bern analysis. Meanwhile, President Donald Trump is restructuring the Department of Justice, dismissing prosecutors involved in investigations against him and freezing funding programs, raising concerns over the separation of powers. In other news, Saïda Keller-Messahli faces defamation charges for her claims about Swiss mosques, and the Munich prosecutor's office investigates real estate mogul René Benko for fraud.
Analysts have made several notable changes in recommendations and price targets for various companies. Abivax's target is reduced to USD 12, while Adecco Group is downgraded to Underperform with a target of CHF 19.50. Notable upgrades include Almirall to buy at EUR 10.45 and SGS SA to buy at CHF 99.
Swiss bank UBS has upgraded Novartis to "Buy" with a price target of 111 francs ahead of the company's Q4 2024 results, due on January 31. Analyst Matthew Weston highlights concerns over the 2025 forecast, particularly the impending patent expiry for Entresto in the USA, which may hinder sales and earnings growth.
UBS has rated NOVARTIS AG as 'Buy', but the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investing in securities carries risks, including the potential total loss of capital, and expert investment advice is recommended. No liability for the accuracy or completeness of the information is assumed, and the content is solely the responsibility of the authors, which may not reflect the views of wallstreetONLINE.
Novartis AG, a leading pharmaceutical company, generates sales primarily from oncology (29.9%), immunology (17.2%), and cardiovascular, renal, and metabolic diseases (14.1%). By the end of 2023, it will operate 33 production sites globally, with sales distributed across Europe (33%), the USA (39.5%), Asia-Africa-Australasia (20.5%), and Canada and Latin America (7%).
UBS has upgraded Novartis to a 'Buy' rating with a target price of 111 francs ahead of the final quarter 2024 figures, expected on January 31. Analyst Matthew Weston highlights investor caution due to the impending patent expiry for Entresto in the USA in mid-2025, which may impact sales and earnings growth.
Donald Trump has returned to the White House, marking the start of his second term amid a bustling earnings season. Netflix led the charge with impressive fourth-quarter results, reporting a surge in subscribers and a net income of $1.87 billion, while major companies like Microsoft and Apple are set to release their figures next week. Despite some market volatility, U.S. indices remain near all-time highs as investors navigate the implications of Trump's pro-business agenda and potential trade policies.
Positive sentiment in markets was driven by hopes of government support, despite a decline in Japan's Nikkei index. The launch of DeepSeek's AI model raised concerns over US tech dominance, impacting shares of major Japanese tech firms. Meanwhile, oil prices fell under pressure from US calls for OPEC to cut prices, and the euro weakened against the franc.
Swiss CEOs, including those from Zurich Insurance and Novartis, are urging Europe to adopt a more dynamic, deregulated approach similar to the U.S. under the new administration. They argue that Europe's regulatory focus is stifling innovation and competitiveness, particularly in technology and pharmaceuticals. As the U.S. pushes for manufacturing growth and tax advantages, European leaders are called to act decisively to enhance their economic landscape.
Novartis AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs warns of rising costs amid anticipated revenue growth and regulatory pressures
07:23 31.01.2025
state subsidies for UBS and trump's power restructuring in the us
Swiss Franc
RICHEMONT, Intellectual Property Services
Alcon Inc.
Novartis AG
Nestlé S.A.
Hoffmann-La Roche AG
USA
DEU
FRA
KOR
CHE
AUT
René Benko
Thomas Milz
Mirjam Moll
Donald Trump
Kash Patel
Show more
06:56 29.01.2025
analysts update recommendations and price targets for major european companies
British Pound Sterling
Swiss Franc
Euro
United States Dollar
UBS Group AG
LVMH Moet Hennessy Louis Vuitton SE
SGS SA
Verallia
Euronext N.V.
The Swatch Group AG
Novartis AG
Alten SA
Show more
08:52 28.01.2025
ubs upgrades novartis to buy ahead of 2024 earnings report
15:36 27.01.2025
ubs rates novartis ag as buy with investment risks highlighted
15:36 27.01.2025
novartis ag reports strong sales across diverse therapeutic areas and regions
15:28 27.01.2025
ubs upgrades novartis to buy with target price of 111 francs
14:36 27.01.2025
trump returns to office as earnings season begins with strong netflix results
United States Dollar
Logitech International S.A.
AMD/BRX
Novartis AG
Netflix, Inc.
Tesla, Inc.
Apple Inc.
Microsoft Corporation
Lonza Group AG
Hoffmann-La Roche AG
Adobe Inc.
USA
MEX
CHE
CAN
Donald Trump
Martin Luther King Jr.
Show more
12:00 27.01.2025
global markets react to ai disruption and economic concerns
Swiss Franc
Euro
United States Dollar
Chinese Yuan
Logitech International S.A.
Novartis AG
ABB Ltd
NVIDIA Corporation
Hoffmann-La Roche AG
JPN
USA
CHN
DEU
Donald Trump
Jun Rong
Show more
06:21 27.01.2025
European leaders urged to embrace deregulation and innovation to compete globally
United States Dollar
Novartis AG
Zurich Insurance Group AG
USA
CHE
Sergio Ermotti
Mario Greco
Robert F. Kennedy
Donald Trump
Vas Narasimhan
Show more
00:01 24.01.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
CEO Changes
Central Bank Actions
GDP Growth & Recession Forecasts
Global Trade Developments
Financial Scams and Security
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Market Analysis and Predictions
Government Policies
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Barclays PLC
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Microsoft Corporation
Credit Suisse Strategic Income I
NVIDIA Corporation
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
End Federal Reserve USD
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Australian Dollar
Canadian Dollar
United Arab Emirates Dirham
Indonesian Rupiah
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Hong Kong Dollar
Mexican Peso
Malaysian Ringgit
Vietnamese Đồng
People: